|
|
|
| home > white papers > Maximize the ROI of Your Post-Approval Research - Bioclinica |
|
|
 WHITE PAPERS |
|
|
Bioclinica
|
|
Maximize the ROI of Your Post-Approval Research
|
|
Expenditures in post-approval (Phase IV) research are going up across
the pharmaceutical, biotech and medical device industries. Given the
resources you’ve committed to post-approval research, you may be
wondering if you’re getting the greatest possible return on your
investment.
Discover how to harness the power of post-approval
research to increase data collection, reduce resource burn, save money,
and maximize your ROI!
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite
Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >> |
|
 |
White Papers |
 |
|
eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials
Clinical Ink
Unlike traditional electronic data capture (EDC),
SureSource, Clinical Ink’s eSource platform, was designed from the
beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides
scientific evidence regarding the impact of SureSource from 517 site
users. Results confirm it significantly reduces workload, lessens
queries, and improves data quality compared to paper and EDC. In this
white paper, we quantitatively evaluate survey outcomes, provide
qualitative feedback from survey respondents, and highlight the observed
benefits of SureSource for transforming clinical research.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
28-31 October 2019, Barcelona, Spain
The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona.
It’s the biggest and most established European vaccine event with over 250 speakers,
700+ senior vaccine attendees, hundreds of networking hours.
It cover key topics across the complete vaccine value chain bringing together:
• Government
• big pharma
• big biotech
• SME Biotech
• academia
and the wider service provider community and their partners to discuss scientific,
clinical and strategic advances and opportunities.
The event has already confirmed over 200 speakers from Human Vaccine Project, OECD,
CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more…
There is a Super Early Bird offer available – Find Out More
www.terrapinn.com/WVCEU/EBR
More info >> |
|
|
|
